文献速递免疫规划传染病防控与疫情报告

EV-A71灭活疫苗上市后多中心安全性监测

[Post-marketing multi-center safety surveillance of inactivated enterovirus A71 vaccine (Vero cell)].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2019-01-01

在浙江、北京、广西、江苏多地选取2016年7月至2018年6月自愿接种EV-A71疫苗的儿童45 239名,共71 243剂次,通过主动监测收集接种后30 min、3 d和30 d内不良反应。总不良反应发生率为1.079%(769剂次),多为轻中度,未见4级不良反应。

要点

  • 总不良反应发生率1.079%,以征集性反应为主(1.047%)。
  • 第1剂不良反应发生率1.281%高于第2剂的0.810%。
  • 局部反应以注射部位发红最常见,全身反应以发热最常见。

核心结论

  • 儿童接种EV-A71疫苗后不良反应发生率较低且多为轻中度,疫苗安全性良好,适合大规模接种。

研究设计与样本

  • 上市后多中心主动监测,选取浙江11个地市、北京丰台区、广西平乐县与钦南区与平果县、江苏东台市为研究现场。
  • 纳入2016年7月至2018年6月自愿自费接种EV-A71疫苗的儿童45 239名,共接种71 243剂次。
  • 北京丰台区和江苏东台市以全部接种者为观察对象,其余地区采用系统抽样。
  • 接种每剂后30 min、30 min至3 d和4~30 d通过现场观察、电话和面访主动监测并收集不良反应。

主要发现

  • 总不良反应发生率为1.079%(769剂次)。
  • 5~11月龄组不良反应发生率最高,为1.182%(177/14 973);≥36月龄组最低,为0.849%(18/2 119)。
  • 征集性不良反应发生率为1.047%(746剂次);1级和2级不良反应发生率分别为0.404%(288剂次)和0.554%(395剂次),未见4级不良反应。
  • 第1剂和第2剂不良反应发生率分别为1.281%(522剂次)和0.810%(247剂次);局部不良反应发生率分别为0.091%(37剂次)和0.043%(13剂次),全身不良反应发生率分别为1.168%(476剂次)和0.760%(232剂次)。
  • 局部反应均主要表现为注射部位发红(第1剂24剂次、第2剂11剂次),全身反应均主要表现为发热(第1剂362剂次、第2剂190剂次);不良反应主要发生在接种后30 min至3 d内,第1剂和第2剂发生率分别为1.016%(414剂次)和0.698%(213剂次)。

临床怎么用

  • 接种后应重点观察30 min至3 d内的不良反应,局部发红和发热为常见表现。
  • 5~11月龄儿童不良反应发生率相对较高,接种后需加强监测。
  • 第1剂不良反应发生率高于第2剂,首剂接种后应做好安全性观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the post-marketing safety profiles of the inactivated enterovirus type 71 (EV-A71) vaccine (Vero cell) after routine inoculation. Methods: Eleven cities of Zhejiang Province, Fengtai district of Beijing, Qinnan district, two counties as Pingle and Pingguo of Guangxi Zhuang Autonomous Region, and Dongtai city of Jiangsu Province were selected as the field sites. A total of 45 239 subjects were enrolled in this study from children who seeked the vaccination of EV-A71 vaccine during the period from July, 2016 to June, 2018. Different sampling method were adopted in different sites. All vaccinated children were invited to participate in the study in Fengtai and Dongtai, however, systematic sampling method were adopted in other sites. Active surveillance was conducted and information about adverse reactions (ARs) occurred in 30 min, 3 d and 30 d following each dose of EV-A71 immunization was collected by field observation, phone-call or face-to-face interview. The incidence of ARs in different types, symptoms and grades were described. Results: In total, there were 45 239 children who received 71 243 doses EV-A71 vaccine. The overall incidence of ARs was 1.079% (769 doses), with the highest incidence of 1.182% (177/14 973) in 5-11 month group and the lowest incidence of 0.849% (18/2 119) in ≥ 36 month group among different age groups. There was a higher incidence in solicited ARs, which was 1.047% (746 doses). The incidences of grade 1 and grade 2 ARs were also higher, which were 0.404% (288 doses) and 0.554% (395 doses), respectively. No grade 4 ARs occurred. The doses of the first and the second vaccination was 40 736 and 30 507, respectively, and the incidences of ARs were 1.281% (522 doses) and 0.810% (247 doses). Also, the incidences of ARs were 0.091% (37 doses) and 0.043% (13 doses) in local, and 1.168% (476 doses) and 0.760% (232 doses) in system. The symptoms of ARs after the two doses of vaccination were basically the same. Redness at the injection site was the most common local ARs after each dose vaccination, with doses of 24 and 11, while fever was the most common systemic ARs, with doses of 362 and 190. Moreover, ARs mainly occurred in 30 min to 3 d after each dose vaccination, with incidence of 1.016% (414 doses) and 0.698% (213 doses) in the first and second dose, respectively. Conclusion: The ARs had a low incidence after vaccination in children and most were mild or moderate. EV-A71 vaccine with good safety is suitable for inoculation in a large scale. 目的: 评价肠道病毒A71型(EV-A71)灭活疫苗(Vero细胞)(EV-A71疫苗)上市后常规接种的安全性。 方法: 选取浙江全省11个地市,北京丰台区,广西壮族自治区平乐县、钦南区、平果县,江苏东台市作为研究现场,以2016年7月至2018年6月期间自愿自费接种EV-A71疫苗的儿童作为研究对象,其中,北京丰台区和江苏东台市以全部接种者作为观察对象;其余地区均采用系统抽样的方式。共45 239名。在接种每剂EV-A71疫苗后30 min、30 min至3 d和4~30 d,通过现场观察、电话和面访的方式主动监测并收集儿童的不良反应发生情况,描述不同种类、症状和级别的不良反应发生率。 结果: 45 239名儿童共接种EV-A71疫苗71 243剂次,总不良反应发生率为1.079%(769剂次);不同年龄组间,5~11月龄组不良反应发生率最高,为1.182%(177/14 973),≥36月龄组最低,为0.849%(18/2 119);征集性不良反应发生率较高,为1.047%(746剂次);1和2级不良反应发生率较高,分别为0.404%(288剂次)和0.554%(395剂次),未见4级不良反应发生。第1和2剂分别接种40 736和30 507剂次,不良反应发生率分别为1.281%(522剂次)和0.810%(247剂次);局部不良反应发生率分别为0.091%(37剂次)和0.043%(13剂次),全身不良反应发生率分别为1.168%(476剂次)和0.760%(232剂次);不良反应症状基本相同,局部反应均主要表现为注射部位发红,分别发生24和11剂次,全身反应均主要表现为发热,分别发生362和190剂次;不良反应均主要发生在接种后30 min至3 d内,发生率分别为1.016%(414剂次)和0.698%(213剂次)。 结论: 儿童接种疫苗后不良反应发生率较低且多为轻中度,EV-A71疫苗安全性良好。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zeng J, Tang T, Wang YJ, et al. [Post-marketing multi-center safety surveillance of inactivated enterovirus A71 vaccine (Vero cell)]. Zhonghua Yu Fang Yi Xue Za Zhi. 2019. PMID: 30841662. doi:10.3760/cma.j.issn.0253-9624.2019.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。